Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of millions of renminbi through Series A+ and Series B financing rounds. The Series B round was led by SDIC, with participation from Efung Capital, Lake VC, Morning Spring Venture, and Jinju Capital. The funds raised will be allocated to enhance market promotion, bolster research and development capabilities, and expand the company’s new product line.
Company Background and Achievements
Founded in 2008, Century Kangtai Bio has earned a reputation for its multiple Category III medical device approvals in the field of ophthalmology. As one of the pioneers in intraocular lens technology in China, the company specializes in the development and manufacturing of foldable intraocular lenses from both hydrophilic and hydrophobic materials. Its prefabricated hydrophobic aspherical intraocular lens received market approval in July of this year, marking a significant milestone for the company.
Proceeds Allocation and Future Outlook
The proceeds from the Series A+ and Series B financing rounds will be instrumental in accelerating the company’s market promotion efforts and strengthening its research and development capabilities. Additionally, the funds will be used to develop new product lines, further solidifying Century Kangtai Bio’s position as a leader in ophthalmic medical devices.-Fineline Info & Tech
